Macular degeneration solutions company MacuLogix closed a $38.7 million financing round, Invision reports.
What you should know:
1. MacuLogix provides instruments, tools and education to treat age-related macular degeneration patients.
2. Vivo Capital led the series D round, with contributions from four other firms.
3. MacuLogix raised a $51 million in venture funding and $10 million in venture debt.
4. "With this funding and the addition of Vivo Capital, we are fully backed by a strategic group of investors who support our company's vision to eliminate blindness caused by AMD," said MacuLogix CEO and President William D. McPhee.